COVID-19 Impact on Noninvasive Cancer Diagnostics Market, Global Research Reports 2020-2021
This report covers market size and forecasts of Noninvasive Cancer Diagnostics, including the following market information:
Major competitors identified in this market include Precision Therapeutics, Inc. (U.S.), A&G Pharmaceutical, Inc. (U.S.), Affymetrix Inc. (U.S.), AVIVA Biosciences Corporation (U.S.), BIOVIEW Inc. (U.S.), Laboratory Corporation of America Holdings (LabCorp) (U.S.), Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.), Digene Corporation (U.S.), Gen-Probe Incorporated (U.S.), IVDiagnostics, Inc. (U.S.), etc.
Based on the Region:
- Global Noninvasive Cancer Diagnostics Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
- Global Noninvasive Cancer Diagnostics Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
- Global Noninvasive Cancer Diagnostics Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
- Global Noninvasive Cancer Diagnostics Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Major competitors identified in this market include Precision Therapeutics, Inc. (U.S.), A&G Pharmaceutical, Inc. (U.S.), Affymetrix Inc. (U.S.), AVIVA Biosciences Corporation (U.S.), BIOVIEW Inc. (U.S.), Laboratory Corporation of America Holdings (LabCorp) (U.S.), Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.), Digene Corporation (U.S.), Gen-Probe Incorporated (U.S.), IVDiagnostics, Inc. (U.S.), etc.
Based on the Region:
- Asia-Pacific (China, Japan, South Korea, India and ASEAN)
- North America (US and Canada)
- Europe (Germany, France, UK and Italy)
- Rest of World (Latin America, Middle East & Africa)
- Clinical Chemistry
- Immunochemistry/Immunoassay
- Molecular Diagnostics
- Others
- Solid Tumors
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Others
1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Noninvasive Cancer Diagnostics Industry
1.7 COVID-19 Impact: Noninvasive Cancer Diagnostics Market Trends
2 GLOBAL NONINVASIVE CANCER DIAGNOSTICS QUARTERLY MARKET SIZE ANALYSIS
2.1 Noninvasive Cancer Diagnostics Business Impact Assessment - COVID-19
2.1.1 Global Noninvasive Cancer Diagnostics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Noninvasive Cancer Diagnostics Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 QUARTERLY COMPETITIVE ASSESSMENT, 2020
3.1 By Players, Global Noninvasive Cancer Diagnostics Quarterly Market Size, 2019 VS 2020
3.2 By Players, Noninvasive Cancer Diagnostics Headquarters and Area Served
3.3 Date of Key Players Enter into Noninvasive Cancer Diagnostics Market
3.4 Key Players Noninvasive Cancer Diagnostics Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 IMPACT OF COVID-19 ON NONINVASIVE CANCER DIAGNOSTICS SEGMENTS, BY TYPE
4.1 Introduction
1.4.1 Clinical Chemistry
1.4.2 Immunochemistry/Immunoassay
1.4.3 Molecular Diagnostics
1.4.4 Others
4.2 By Type, Global Noninvasive Cancer Diagnostics Market Size, 2019-2021
5 IMPACT OF COVID-19 ON NONINVASIVE CANCER DIAGNOSTICS SEGMENTS, BY APPLICATION
5.1 Overview
5.5.1 Solid Tumors
5.5.2 Blood Cancer
5.5.3 Lung Cancer
5.5.4 Breast Cancer
5.5.5 Others
5.2 By Application, Global Noninvasive Cancer Diagnostics Market Size, 2019-2021
5.2.1 By Application, Global Noninvasive Cancer Diagnostics Market Size by Application, 2019-2021
6 GEOGRAPHIC ANALYSIS
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 COMPANY PROFILES
7.1 Precision Therapeutics, Inc. (U.S.)
7.1.1 Precision Therapeutics, Inc. (U.S.) Business Overview
7.1.2 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.1.3 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.1.4 Precision Therapeutics, Inc. (U.S.) Response to COVID-19 and Related Developments
7.2 A&G Pharmaceutical, Inc. (U.S.)
7.2.1 A&G Pharmaceutical, Inc. (U.S.) Business Overview
7.2.2 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.2.3 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.2.4 A&G Pharmaceutical, Inc. (U.S.) Response to COVID-19 and Related Developments
7.3 Affymetrix Inc. (U.S.)
7.3.1 Affymetrix Inc. (U.S.) Business Overview
7.3.2 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.3.3 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.3.4 Affymetrix Inc. (U.S.) Response to COVID-19 and Related Developments
7.4 AVIVA Biosciences Corporation (U.S.)
7.4.1 AVIVA Biosciences Corporation (U.S.) Business Overview
7.4.2 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.4.3 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.4.4 AVIVA Biosciences Corporation (U.S.) Response to COVID-19 and Related Developments
7.5 BIOVIEW Inc. (U.S.)
7.5.1 BIOVIEW Inc. (U.S.) Business Overview
7.5.2 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.5.3 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.5.4 BIOVIEW Inc. (U.S.) Response to COVID-19 and Related Developments
7.6 Laboratory Corporation of America Holdings (LabCorp) (U.S.)
7.6.1 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Business Overview
7.6.2 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.6.3 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.6.4 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Response to COVID-19 and Related Developments
7.7 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
7.7.1 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Business Overview
7.7.2 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.7.3 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.7.4 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Response to COVID-19 and Related Developments
7.8 Digene Corporation (U.S.)
7.8.1 Digene Corporation (U.S.) Business Overview
7.8.2 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.8.3 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.8.4 Digene Corporation (U.S.) Response to COVID-19 and Related Developments
7.9 Gen-Probe Incorporated (U.S.)
7.9.1 Gen-Probe Incorporated (U.S.) Business Overview
7.9.2 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.9.3 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.9.4 Gen-Probe Incorporated (U.S.) Response to COVID-19 and Related Developments
7.10 IVDiagnostics, Inc. (U.S.)
7.10.1 IVDiagnostics, Inc. (U.S.) Business Overview
7.10.2 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.10.3 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.10.4 IVDiagnostics, Inc. (U.S.) Response to COVID-19 and Related Developments
8 KEY FINDINGS
9 APPENDIX
9.1 About US
9.2 Disclaimer
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Noninvasive Cancer Diagnostics Industry
1.7 COVID-19 Impact: Noninvasive Cancer Diagnostics Market Trends
2 GLOBAL NONINVASIVE CANCER DIAGNOSTICS QUARTERLY MARKET SIZE ANALYSIS
2.1 Noninvasive Cancer Diagnostics Business Impact Assessment - COVID-19
2.1.1 Global Noninvasive Cancer Diagnostics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Noninvasive Cancer Diagnostics Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 QUARTERLY COMPETITIVE ASSESSMENT, 2020
3.1 By Players, Global Noninvasive Cancer Diagnostics Quarterly Market Size, 2019 VS 2020
3.2 By Players, Noninvasive Cancer Diagnostics Headquarters and Area Served
3.3 Date of Key Players Enter into Noninvasive Cancer Diagnostics Market
3.4 Key Players Noninvasive Cancer Diagnostics Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 IMPACT OF COVID-19 ON NONINVASIVE CANCER DIAGNOSTICS SEGMENTS, BY TYPE
4.1 Introduction
1.4.1 Clinical Chemistry
1.4.2 Immunochemistry/Immunoassay
1.4.3 Molecular Diagnostics
1.4.4 Others
4.2 By Type, Global Noninvasive Cancer Diagnostics Market Size, 2019-2021
5 IMPACT OF COVID-19 ON NONINVASIVE CANCER DIAGNOSTICS SEGMENTS, BY APPLICATION
5.1 Overview
5.5.1 Solid Tumors
5.5.2 Blood Cancer
5.5.3 Lung Cancer
5.5.4 Breast Cancer
5.5.5 Others
5.2 By Application, Global Noninvasive Cancer Diagnostics Market Size, 2019-2021
5.2.1 By Application, Global Noninvasive Cancer Diagnostics Market Size by Application, 2019-2021
6 GEOGRAPHIC ANALYSIS
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 COMPANY PROFILES
7.1 Precision Therapeutics, Inc. (U.S.)
7.1.1 Precision Therapeutics, Inc. (U.S.) Business Overview
7.1.2 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.1.3 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.1.4 Precision Therapeutics, Inc. (U.S.) Response to COVID-19 and Related Developments
7.2 A&G Pharmaceutical, Inc. (U.S.)
7.2.1 A&G Pharmaceutical, Inc. (U.S.) Business Overview
7.2.2 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.2.3 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.2.4 A&G Pharmaceutical, Inc. (U.S.) Response to COVID-19 and Related Developments
7.3 Affymetrix Inc. (U.S.)
7.3.1 Affymetrix Inc. (U.S.) Business Overview
7.3.2 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.3.3 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.3.4 Affymetrix Inc. (U.S.) Response to COVID-19 and Related Developments
7.4 AVIVA Biosciences Corporation (U.S.)
7.4.1 AVIVA Biosciences Corporation (U.S.) Business Overview
7.4.2 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.4.3 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.4.4 AVIVA Biosciences Corporation (U.S.) Response to COVID-19 and Related Developments
7.5 BIOVIEW Inc. (U.S.)
7.5.1 BIOVIEW Inc. (U.S.) Business Overview
7.5.2 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.5.3 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.5.4 BIOVIEW Inc. (U.S.) Response to COVID-19 and Related Developments
7.6 Laboratory Corporation of America Holdings (LabCorp) (U.S.)
7.6.1 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Business Overview
7.6.2 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.6.3 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.6.4 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Response to COVID-19 and Related Developments
7.7 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
7.7.1 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Business Overview
7.7.2 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.7.3 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.7.4 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Response to COVID-19 and Related Developments
7.8 Digene Corporation (U.S.)
7.8.1 Digene Corporation (U.S.) Business Overview
7.8.2 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.8.3 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.8.4 Digene Corporation (U.S.) Response to COVID-19 and Related Developments
7.9 Gen-Probe Incorporated (U.S.)
7.9.1 Gen-Probe Incorporated (U.S.) Business Overview
7.9.2 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.9.3 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.9.4 Gen-Probe Incorporated (U.S.) Response to COVID-19 and Related Developments
7.10 IVDiagnostics, Inc. (U.S.)
7.10.1 IVDiagnostics, Inc. (U.S.) Business Overview
7.10.2 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Quarterly Revenue, 2020
7.10.3 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product Introduction
7.10.4 IVDiagnostics, Inc. (U.S.) Response to COVID-19 and Related Developments
8 KEY FINDINGS
9 APPENDIX
9.1 About US
9.2 Disclaimer
LIST OF TABLES
Table 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Noninvasive Cancer Diagnostics Assessment
Table 9. COVID-19 Impact: Noninvasive Cancer Diagnostics Market Trends
Table 10. COVID-19 Impact Global Noninvasive Cancer Diagnostics Market Size
Table 11. Global Noninvasive Cancer Diagnostics Quarterly Market Size, 2020 (US$ Million)
Table 12. Global Noninvasive Cancer Diagnostics Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 13. Global Noninvasive Cancer Diagnostics Market Growth Drivers
Table 14. Global Noninvasive Cancer Diagnostics Market Restraints
Table 15. Global Noninvasive Cancer Diagnostics Market Opportunities
Table 16. Global Noninvasive Cancer Diagnostics Market Challenges
Table 17. By Players, Noninvasive Cancer Diagnostics Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 18. Key Players, Noninvasive Cancer Diagnostics Revenue Market Share, 2019 VS 2020 (%)
Table 19. Key Noninvasive Cancer Diagnostics Players Headquarters and Area Served
Table 20. Date of Key Players Enter into Noninvasive Cancer Diagnostics Market
Table 21. Key Players Noninvasive Cancer Diagnostics Product Type
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. By Players, Global Noninvasive Cancer Diagnostics Market Size 2019-2021, (US$ Million)
Table 24. Global Noninvasive Cancer Diagnostics Market Size by Application: 2019-2021 (US$ Million)
Table 25. Global Noninvasive Cancer Diagnostics Market Size by Region, 2019-2021 (US$ Million)
Table 26. By Country, North America Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 27. By Type, US Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 28. By Application, US Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 29. By Type, Canada Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 30. By Application, Canada Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 31. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 32. By Country, Europe Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 33. By Type, Germany Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 34. By Application, Germany Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 35. By Type, France Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 36. By Application, France Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 37. By Type, UK Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 38. By Application, UK Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 39. By Type, Italy Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 40. By Application, Italy Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 41. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 42. By Region, Asia-Pacific Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 43. By Type, China Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 44. By Application, China Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 45. By Type, Japan Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 46. By Application, Japan Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 47. By Type, South Korea Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 48. By Application, South Korea Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 49. By Type, India Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 50. By Application, India Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 51. By Type, ASEAN Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 52. By Application, ASEAN Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 53. By Type, Latin America Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 54. By Application, Latin America Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 55. By Type, Middle East and Africa Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 56. By Application, Middle East and Africa Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 57. Precision Therapeutics, Inc. (U.S.) Business Overview
Table 58. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 60. Precision Therapeutics, Inc. (U.S.) Response to COVID-19 and Related Developments
Table 61. A&G Pharmaceutical, Inc. (U.S.) Business Overview
Table 62. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 64. A&G Pharmaceutical, Inc. (U.S.) Response to COVID-19 and Related Developments
Table 65. Affymetrix Inc. (U.S.) Business Overview
Table 66. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 68. Affymetrix Inc. (U.S.) Response to COVID-19 and Related Developments
Table 69. AVIVA Biosciences Corporation (U.S.) Business Overview
Table 70. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Product
Table 72. AVIVA Biosciences Corporation (U.S.) Response to COVID-19 and Related Developments
Table 73. BIOVIEW Inc. (U.S.) Business Overview
Table 74. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 76. BIOVIEW Inc. (U.S.) Response to COVID-19 and Related Developments
Table 77. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Business Overview
Table 78. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 79. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Product
Table 80. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Response to COVID-19 and Related Developments
Table 81. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Business Overview
Table 82. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 83. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 84. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Response to COVID-19 and Related Developments
Table 85. Digene Corporation (U.S.) Business Overview
Table 86. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 87. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Product
Table 88. Digene Corporation (U.S.) Response to COVID-19 and Related Developments
Table 89. Gen-Probe Incorporated (U.S.) Business Overview
Table 90. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 91. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Product
Table 92. Gen-Probe Incorporated (U.S.) Response to COVID-19 and Related Developments
Table 93. IVDiagnostics, Inc. (U.S.) Business Overview
Table 94. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 95. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 96. IVDiagnostics, Inc. (U.S.) Response to COVID-19 and Related Developments
Table 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Noninvasive Cancer Diagnostics Assessment
Table 9. COVID-19 Impact: Noninvasive Cancer Diagnostics Market Trends
Table 10. COVID-19 Impact Global Noninvasive Cancer Diagnostics Market Size
Table 11. Global Noninvasive Cancer Diagnostics Quarterly Market Size, 2020 (US$ Million)
Table 12. Global Noninvasive Cancer Diagnostics Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 13. Global Noninvasive Cancer Diagnostics Market Growth Drivers
Table 14. Global Noninvasive Cancer Diagnostics Market Restraints
Table 15. Global Noninvasive Cancer Diagnostics Market Opportunities
Table 16. Global Noninvasive Cancer Diagnostics Market Challenges
Table 17. By Players, Noninvasive Cancer Diagnostics Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 18. Key Players, Noninvasive Cancer Diagnostics Revenue Market Share, 2019 VS 2020 (%)
Table 19. Key Noninvasive Cancer Diagnostics Players Headquarters and Area Served
Table 20. Date of Key Players Enter into Noninvasive Cancer Diagnostics Market
Table 21. Key Players Noninvasive Cancer Diagnostics Product Type
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. By Players, Global Noninvasive Cancer Diagnostics Market Size 2019-2021, (US$ Million)
Table 24. Global Noninvasive Cancer Diagnostics Market Size by Application: 2019-2021 (US$ Million)
Table 25. Global Noninvasive Cancer Diagnostics Market Size by Region, 2019-2021 (US$ Million)
Table 26. By Country, North America Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 27. By Type, US Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 28. By Application, US Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 29. By Type, Canada Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 30. By Application, Canada Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 31. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 32. By Country, Europe Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 33. By Type, Germany Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 34. By Application, Germany Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 35. By Type, France Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 36. By Application, France Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 37. By Type, UK Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 38. By Application, UK Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 39. By Type, Italy Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 40. By Application, Italy Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 41. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 42. By Region, Asia-Pacific Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 43. By Type, China Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 44. By Application, China Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 45. By Type, Japan Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 46. By Application, Japan Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 47. By Type, South Korea Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 48. By Application, South Korea Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 49. By Type, India Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 50. By Application, India Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 51. By Type, ASEAN Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 52. By Application, ASEAN Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 53. By Type, Latin America Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 54. By Application, Latin America Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 55. By Type, Middle East and Africa Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 56. By Application, Middle East and Africa Noninvasive Cancer Diagnostics Market Size, 2019-2021 (US$ Million)
Table 57. Precision Therapeutics, Inc. (U.S.) Business Overview
Table 58. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 60. Precision Therapeutics, Inc. (U.S.) Response to COVID-19 and Related Developments
Table 61. A&G Pharmaceutical, Inc. (U.S.) Business Overview
Table 62. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 64. A&G Pharmaceutical, Inc. (U.S.) Response to COVID-19 and Related Developments
Table 65. Affymetrix Inc. (U.S.) Business Overview
Table 66. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 68. Affymetrix Inc. (U.S.) Response to COVID-19 and Related Developments
Table 69. AVIVA Biosciences Corporation (U.S.) Business Overview
Table 70. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Product
Table 72. AVIVA Biosciences Corporation (U.S.) Response to COVID-19 and Related Developments
Table 73. BIOVIEW Inc. (U.S.) Business Overview
Table 74. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 76. BIOVIEW Inc. (U.S.) Response to COVID-19 and Related Developments
Table 77. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Business Overview
Table 78. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 79. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Product
Table 80. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Response to COVID-19 and Related Developments
Table 81. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Business Overview
Table 82. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 83. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 84. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Response to COVID-19 and Related Developments
Table 85. Digene Corporation (U.S.) Business Overview
Table 86. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 87. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Product
Table 88. Digene Corporation (U.S.) Response to COVID-19 and Related Developments
Table 89. Gen-Probe Incorporated (U.S.) Business Overview
Table 90. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 91. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Product
Table 92. Gen-Probe Incorporated (U.S.) Response to COVID-19 and Related Developments
Table 93. IVDiagnostics, Inc. (U.S.) Business Overview
Table 94. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 95. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product
Table 96. IVDiagnostics, Inc. (U.S.) Response to COVID-19 and Related Developments
LIST OF FIGURES
Figure 1. Noninvasive Cancer Diagnostics Product Picture
Figure 2. Noninvasive Cancer Diagnostics Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Noninvasive Cancer Diagnostics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Noninvasive Cancer Diagnostics Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Noninvasive Cancer Diagnostics Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Noninvasive Cancer Diagnostics Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Noninvasive Cancer Diagnostics Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Noninvasive Cancer Diagnostics Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Noninvasive Cancer Diagnostics Market Size Market Share, 2019-2021
Figure 1. Noninvasive Cancer Diagnostics Product Picture
Figure 2. Noninvasive Cancer Diagnostics Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Noninvasive Cancer Diagnostics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Noninvasive Cancer Diagnostics Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Noninvasive Cancer Diagnostics Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Noninvasive Cancer Diagnostics Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Noninvasive Cancer Diagnostics Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Noninvasive Cancer Diagnostics Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Noninvasive Cancer Diagnostics Market Size Market Share, 2019-2021
